Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magovčević-Liebisch, Ph.D., J.D., to Board of Directors

Core Insights - Acrivon Therapeutics has appointed Dr. Ivana Magovčević-Liebisch to its board of directors, bringing over 25 years of experience in global business and R&D operations [2][3] Company Overview - Acrivon Therapeutics is a clinical stage biopharmaceutical company focused on developing precision oncology medicines using its proprietary platform, Acrivon Predictive Precision Proteomics (AP3) [4] - The AP3 platform is designed to identify patients whose tumors are likely to respond to specific treatments by analyzing the tumor cell protein signaling network and drug resistance mechanisms [4] - Acrivon is advancing its lead candidate, ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, currently in a potentially registrational Phase 2 trial for multiple tumor types [4] - ACR-368 has received Fast Track designation from the FDA for use as monotherapy in patients with platinum-resistant ovarian or endometrial cancer [4] - The ACR-368 OncoSignature test, which is still pending regulatory approval, has been evaluated in preclinical studies and has received Breakthrough Device designation from the FDA [4] Leadership Insights - Dr. Magovčević-Liebisch has a strong background in leading business development and commercialization efforts, having previously held executive roles at Vigil Neuroscience, Ipsen, and Teva Pharmaceutical Industries [2] - She has a Ph.D. in genetics from Harvard University and a J.D. in high technology law, indicating a robust academic foundation to support her role at Acrivon [2][3]